Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.350
-0.070 (-4.93%)
May 6, 2025, 9:47 AM EDT - Market open
Acrivon Therapeutics Employees
As of December 31, 2024, Acrivon Therapeutics had 78 total employees, including 75 full-time and 3 part-time employees. The number of employees increased by 17 or 27.87% compared to the previous year.
Employees
78
Change (1Y)
17
Growth (1Y)
27.87%
Revenue / Employee
n/a
Profits / Employee
-$1,032,769
Market Cap
42.32M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 78 | 17 | 27.87% |
Dec 31, 2023 | 61 | 17 | 38.64% |
Dec 31, 2022 | 44 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ACRV News
- 11 days ago - Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 - GlobeNewsWire
- 4 weeks ago - Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer - GlobeNewsWire
- 5 weeks ago - Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 6 weeks ago - Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates - GlobeNewsWire
- 5 months ago - Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
- 7 months ago - Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 months ago - Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - GlobeNewsWire
- 8 months ago - Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects - Seeking Alpha